TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Palisade Bio ( (PALI) ) has issued an update.
On December 3, 2025, Palisade Bio held a special meeting of stockholders where key proposals were approved. The stockholders approved the issuance of up to 8,637,810 shares of common stock underlying certain warrants, an amendment to increase the number of authorized shares of common stock from 280,000,000 to 300,000,000, and a proposal to adjourn the meeting if necessary to solicit additional proxies.
The most recent analyst rating on (PALI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Average Trading Volume: 8,184,186
Technical Sentiment Signal: Sell
Current Market Cap: $272.7M
For detailed information about PALI stock, go to TipRanks’ Stock Analysis page.